Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis - Wikidata - awgldk - TriplyDB

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis

http://www.wikidata.org/entity/Q28075536

about

Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?Crohn's Strictures-Moving Away from the Knife Purinergic receptors: new targets for the treatment of gout and fibrosis.Intestinal fibrosis: ready to be reversed.The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis.Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen.Idiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age.Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia.Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.Nintedanib for Idiopathic Pulmonary Fibrosis.Tolerability of treatment with pirfenidone or nintedanib for pulmonary fibrosis in the real world.Pirfenidone reduces subchondral bone loss and fibrosis after murine knee cartilage injury.Effect of nintedanib on airway inflammation and remodeling in a murine chronic asthma model.Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants.Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis.Idiopathic Pulmonary Fibrosis (IPF): An Overview Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice

P2860

Q38598382-7F4686D6-A69F-46E4-9DD2-7C1BC7760540 Q38663704-26EB7EA1-4DC1-4554-B3F9-DC1A82E6903E Q39019348-264D0778-F82A-47E8-A06B-54F3D52A4F31 Q39237846-A46224EE-2C7D-4D38-8CB1-9DEB87FCD421 Q39344375-39E7775F-8C5C-446F-8F2C-7FCA7EFA819F Q41809872-D1446B36-E405-4BB8-A3C1-A854C94B937F Q47110170-B21DD7D8-CF6F-4EDF-ABD4-8B1AC417B41D Q47191410-7ABF88E9-B5B8-4737-89B0-BEB962F3C9BA Q47791471-FB8C97F6-B55C-455E-952B-71428B7E00E6 Q47826077-F6F598FE-A6FB-406D-983A-794FCEEDEAF7 Q47910696-A67E30D7-601B-440D-8D60-C49A5CD6ADD3 Q47990145-F38237AA-6876-4DED-87A0-D8F1518C5D3D Q48144212-76F63A72-BF3B-4C8C-B71D-C65EBE133510 Q49897554-55C47D86-D7AD-4B82-832C-0F7AF8A86B96 Q51410548-102FCC5D-4B4F-401A-ABDF-C75CCB16B090 Q52659102-C96B75E5-F572-4AAF-AEBA-9772CD2DB656 Q55009120-5FB6D3D4-8E0A-4BFF-A0DF-3653AC81AD9F Q57170607-04F3ABA2-28DC-48F3-B793-7F0B5FE421B7 Q57811298-12D90847-C741-4211-8C3C-90B5F8446CA9 Q58587295-ECD2EC43-93C6-4165-BAE0-6EC0585B1A4F Q58587321-8677AE67-42BB-40E4-A5CD-0BFB3167A286

P2860

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis

http://www.wikidata.org/entity/Q28075536

description

2016 nî lūn-bûn

@nan

2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Real World Experiences: Pirfen ...... Idiopathic Pulmonary Fibrosis

@ast

Real World Experiences: Pirfen ...... Idiopathic Pulmonary Fibrosis

@en

Real World Experiences: Pirfen ...... Idiopathic Pulmonary Fibrosis

@nl

type

label

Real World Experiences: Pirfen ...... Idiopathic Pulmonary Fibrosis

@ast

Real World Experiences: Pirfen ...... Idiopathic Pulmonary Fibrosis

@en

Real World Experiences: Pirfen ...... Idiopathic Pulmonary Fibrosis

@nl

prefLabel

Real World Experiences: Pirfen ...... Idiopathic Pulmonary Fibrosis

@ast

Real World Experiences: Pirfen ...... Idiopathic Pulmonary Fibrosis

@en

Real World Experiences: Pirfen ...... Idiopathic Pulmonary Fibrosis

@nl

P1433

Q28075536-602EBE95-162D-43BB-B309-99DB756E7B3E

P1476

Q28075536-3EE908A7-1FB3-4426-9D95-557D28FE3F0B

P2093

Q28075536-14E71999-6A5F-4CEE-BC33-08724B36EC3F

Q28075536-63DE88BB-97AF-4B20-99C7-1A4965491DA3

Q28075536-87FD7E9F-257B-4111-8677-2C3B5C0B0BFB

P2860

Q28075536-064CF66E-1A49-4FD2-AEB4-3EE585A57AFA

Q28075536-1E8B4C05-9486-4566-9FDB-EA4566FD42EC

Q28075536-422CD86B-A693-4767-B859-9300A7AC71A0

Q28075536-432F0041-26EF-4585-A846-1BBC7404EC7F

Q28075536-4F84A79E-222D-41A9-BF71-77A66E498085

Q28075536-6E39F439-41C9-4768-83D8-0DF0FC3BA6F9

Q28075536-7C718BC7-F8B6-4E9A-82B2-4C2B3139C0EF

Q28075536-84B9E261-51A8-4E38-AB81-27ABEC7AE9F8

Q28075536-9DE4DF9B-0F62-4486-980E-287A7A0CECC2

Q28075536-A4FCE228-EBB9-418B-9DE3-30A4E1684CD8

P31

Q28075536-89DBD868-EB4B-4DCF-B366-E62088A709BB

P3181

Q28075536-D1268735-EC36-47CD-B0A5-92592BFFFA0D

P356

Q28075536-4D0D2230-6EA9-4AC3-85FB-96C8DB87B5D4

P407

Q28075536-2DCFE92E-F97F-4D61-AB34-F8A6D081EF8A

P433

Q28075536-47E44E8F-472D-4358-AFC1-3E49027D69B0

P478

Q28075536-0636205D-FBFF-491E-9777-C47BB6E28EC3

P50

Q28075536-06E22C1E-1B98-4357-B6B3-C11074E6D17C

Q28075536-21E970E3-173C-4FD0-8533-1256E88C8E2F

P577

Q28075536-C58FEA3D-2921-4D9E-B15B-16F4D37A07C6

P698

Q28075536-E657C276-8D8E-4BF4-BA2A-E62F8EE69D51

P921

Q28075536-47A7A13D-161F-4A81-A609-540036479758

Q28075536-88AF043C-6A32-4027-8695-A2CCBC59DB09

P932

Q28075536-38975336-81A5-4E74-97FC-7E3054BBA980

P3181

P356

P1433

Journal of Clinical Medicine

P1476

Real World Experiences: Pirfen ...... Idiopathic Pulmonary Fibrosis

@en

P2093

Colm Leonard

http://www.w3.org/2001/XMLSchema#string

Hannah Toellner

http://www.w3.org/2001/XMLSchema#string

Helen Morris

http://www.w3.org/2001/XMLSchema#string

P2860

Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.

Nintedanib in the treatment of idiopathic pulmonary fibrosis.

Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis

Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis.

Clinical course and prediction of survival in idiopathic pulmonary fibrosis.

The pathogenesis of idiopathic pulmonary fibrosis.

P31

scholarly article

P3181

3690991

http://www.w3.org/2001/XMLSchema#string

P356

10.3390/JCM5090078

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Nazia Chaudhuri

P577

2016-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27598213

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary fibrosis

P932

5039481

http://www.w3.org/2001/XMLSchema#string